-
Posted by
Two Blokes Jul 12 -
Filed in
Stock
-
5 views
With Illumina's divestiture of GRAIL, the company will improve its operating expenses, since GRAIL reported significant losses while it was part of Illumina. The global DNA sequencing market is expected to grow at a CAGR of 9% from 2024 and 2028, which is a positive aspect for Illumina. Illumina has reported higher gross profit margins than its peers, which reflects that its core business is profitable.
